Medtronic (MDT)
Builds medical devices for cardiac, neurological, surgical, and patient-monitoring care.
Something off on this page? Send us feedback.
Develops device-based therapies across cardiovascular, neuroscience, and medical-surgical care, from pacemakers and heart valves to spine systems, surgical tools, robotics, and patient monitors. Revenue is globally balanced, while the separately listed MiniMed diabetes business remains consolidated pending further separation.
Develops and sells device-based therapies through the Cardiovascular, Neuroscience, and Medical Surgical portfolios. Products span pacemakers and defibrillators, cardiac ablation and valves, vascular interventions, spine and cranial systems, neuromodulation, surgical instruments and robotics, endoscopy, and patient monitoring. Specialist-organized sales teams supply hospitals, ambulatory centers, and physicians across a roughly even mix of U.S. and international revenue.
Combines implantable-device franchises with imaging, navigation, robotics, remote monitoring, and consumables to support clinical workflows across multiple specialties. The separately listed MiniMed diabetes business remains a controlled, consolidated subsidiary while further separation is planned. Sales depend on product approvals, manufacturing quality, clinical evidence and adoption, reimbursement, hospital purchasing, and continuity for regulated components that can be difficult to replace.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 3, 2026 | Deutsche Bank | Reiterate | Rating: —Target: $80 | Target: $92 |
| Sep 3, 2026 | UBS | Reiterate | Rating: —Target: $100 | Target: $110 |
| Sep 2, 2026 | Mizuho Securities | Target | Target: $100 | Target: $115 |
| Sep 2, 2026 | Stifel Nicolaus | Target | Target: $80 | Target: $95 |
| Sep 2, 2026 | Wells Fargo | Reiterate | Rating: —Target: $114 | Target: $104 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $8.82B · Total debt $28.15B · Total assets $93.31B · Shareholders' equity $50.23B
- Revenue
- $9.76B
- Operating income
- $1.76B
- Net income
- $1.47B
HistoryDividendAnnual yieldUpcoming
| Institutions | 86.06% | 1.10B shares | |
|---|---|---|---|
| 2,202 holders · as of Jun 30, 2026 | |||
| Insiders | 0.09% | 1.20M shares | |
| 26 holders · as of Sep 17, 2026 | |||
| Other | 13.85% | 177.22M shares | |
| remainder | |||
1.28B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.91% | 114.02M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.55% | 83.82M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.95% | 63.40M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 2.66% | 34.06M | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.36% | 30.19M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Harry Skip Kiil | officer: EVP & President Cardiovascular | −1,483 | $93.65 |
| Jul 8, 2026 | Matthew R. Walter | officer: SVP, Chief HR Officer | −3,102 | $83.15 |
| Jun 8, 2026 | Harry Skip Kiil | officer: EVP & President Cardiovascular | −4,189 | $80.44 |
| Feb 19, 2026 | Harry Skip Kiil | officer: EVP & President Cardiovascular | −52,524 | $97.71 |
| Nov 19, 2025 | Gregory L. Smith | officer: EVP Global Ops & Supply Chain | −30,000 | $101.95 |
- Abbott
Widest cross-segment rival: cardiac rhythm, EP, structural heart, and diabetes.
- Boston Scientific
Primary head-to-head rival in cardiac ablation, CRM, and neuromodulation.
- Edwards Lifesciences
TAVR duopoly rival; SAPIEN vs Evolut defines the structural heart valve race.
- Globus Medical
Neck-and-neck spine market rival post-NuVasive merger; ExcelsiusGPS vs Mazor X.
- Intuitive Surgical
Soft-tissue robotics leader; da Vinci vs Hugo RAS as primary challenger.
- Johnson & Johnson
Cross-segment rival in EP, surgical instruments/stapling, spine, and robotics.
- Stryker
Spine robotics and neurotechnology rival; Mako 4 vs Mazor X in guided surgery.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Medtronic | $90.88 | +0.12% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Abbott | $104.00 | +0.27% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Boston Scientific | $44.94 | +0.01% | $64.98B | 17.8 | 13.7 | 3.1 | +7.5% |
| Edwards Lifesciences | $88.78 | −0.02% | $50.87B | 50.8 | 28.3 | 7.8 | +13.6% |
| Globus Medical | $75.19 | −0.03% | $10.02B | 19.1 | 14.7 | 3.2 | +5.9% |
| Intuitive Surgical | $402.99 | +0.27% | $141.89B | 45.7 | 35.5 | 12.9 | +18.5% |
| Johnson & Johnson | $269.17 | −0.04% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Stryker | $275.09 | +0.01% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Median | 31.2 | 17.9 | 4.1 | +9.4% |